Farletuzumab

Drug Overview

Farletuzumab is a specialized medicine used in the field of oncology. It is a “smart” drug, which means it is designed to find and attack specific cancer cells while trying to leave healthy cells alone. It belongs to a class of medicines called monoclonal antibodies. These are laboratory-made proteins that act like heat-seeking missiles to find certain markers on the surface of a tumor.

Here are the key details about this agent:

• Generic Name: Farletuzumab (also known as MORAb-003).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Monoclonal Antibody / Folate Receptor Alpha (FR-alpha) Inhibitor.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is being actively studied in advanced clinical trials for ovarian and lung cancers.

What Is It and How Does It Work? (Mechanism of Action)

To understand how farletuzumab works, it helps to know how cancer cells “eat.” Many cancer cells, especially those in the ovaries and lungs, have a huge hunger for a nutrient called folate (a type of Vitamin B). To catch this nutrient, the cells grow special “catchers” on their surface called Folate Receptor Alpha (FR-alpha).

Farletuzumab is designed to be a “Targeted Therapy.” Here is how it works at the molecular level:

1. Finding the Target: Farletuzumab travels through the blood until it finds a cell with many FR-alpha receptors. Normal healthy cells usually have very few of these, so the drug ignores them.
2. The Molecular Lock: The drug binds tightly to the FR-alpha receptor. This acts like a “cap” on the receptor, preventing the cancer cell from using it to pull in nutrients.
3. Signaling Shutdown: By binding to the receptor, farletuzumab interferes with the cell’s internal signaling pathways (specifically the Lyn kinase pathway). This signal normally tells the cell to keep growing and dividing. When the signal is blocked, the cell’s growth slows down.
4. Immune System Recruitment: Once farletuzumab is stuck to the cancer cell, it acts like a “flag” for the immune system. This triggers Antibody-Dependent Cellular Cytotoxicity (ADCC). This is a process where the body’s natural killer cells see the flag, realize the cell is an intruder, and destroy it.
5. Complement Activation: It can also activate the “complement system,” which is a group of blood proteins that can punch holes in the cancer cell’s wall to kill it.

FDA Approved Clinical Indications

Because farletuzumab is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Ovarian Cancer: Used in patients whose cancer has returned (relapsed) and is sensitive to platinum-based chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): Investigated for tumors that show high levels of the Folate Receptor Alpha.
• Peritoneal and Fallopian Tube Cancers: Since these are biologically similar to ovarian cancer, they are often included in the same trials.

Non-oncological Uses:

• There are currently no non-oncological uses being studied for farletuzumab.

Dosage and Administration Protocols

Farletuzumab is given as a liquid through a needle into a vein. Because it is a protein-based medicine, it must be given slowly to ensure the patient does not have an allergic reaction.

Note: Since the drug is a large protein processed by the immune system, standard dose adjustments for mild kidney (renal) or liver (hepatic) issues are generally not required, but doctors monitor these organs closely during treatment.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have focused on using farletuzumab in combination with other treatments to make it more effective.

• Ovarian Cancer Success: In Phase 2 and Phase 3 trials (such as the MORAb-003-004 study), researchers looked at adding farletuzumab to standard chemotherapy. While it did not help every patient, a specific group of patients with low levels of a protein called CA-125 saw a significant increase in progression-free survival (PFS). This means the time the cancer stayed away was extended by several months.
• Next-Generation Combinations: Recent research has shifted toward Farletuzumab Ecteribulin, a “conjugate” drug. This is farletuzumab with a powerful chemotherapy drug already attached to it. Early data shows this new version can shrink tumors in up to 25-30% of patients with very resistant ovarian cancer.
• Targeting the Right Patients: Modern studies show that patients with the highest “expression” (amount) of Folate Receptor Alpha on their tumors respond best, leading to better disease control rates compared to standard care.

Safety Profile and Side Effects

Farletuzumab is generally better tolerated than standard chemotherapy because it is more targeted. However, because it is an IV protein, it has specific side effects.

Black Box Warning:

• There is no FDA Black Box Warning for farletuzumab.

Common Side Effects (>10%):

• Infusion Reactions: Chills, fever, or a slight itchy rash during the injection.
• Fatigue: Feeling very tired or lacking energy.
• Nausea: Mild stomach upset.
• Headache: Dull aches that usually go away with standard over-the-counter medicine.

Serious Adverse Events:

• Severe Allergic Reactions (Anaphylaxis): Rare but serious trouble breathing or swelling of the face during the infusion.
• Bowel Issues: In rare cases, inflammation of the digestive tract.

Management Strategies:

• Pre-medication: Patients are often given an antihistamine (like Benadryl) and a fever reducer (like Tylenol) 30 to 60 minutes before the infusion to prevent reactions.
• Observation: The medical team monitors heart rate and blood pressure closely during the injection.
• Slowing the Drip: If a mild reaction occurs, the nurse can slow down the infusion to make it more comfortable.

Research Areas

Farletuzumab is a major focus in Immunotherapy research. Scientists are looking at whether this drug can be combined with “checkpoint inhibitors” (like Pembrolizumab). The idea is that farletuzumab “unmasks” the cancer cell, and the immunotherapy then helps the immune system finish the job.

There is also research into Regenerative Medicine regarding how folate receptors behave in healthy tissue repair. While farletuzumab is used to kill cancer, understanding the folate pathway helps researchers learn how to protect healthy stem cells during aggressive cancer treatments.

Patient Management and Practical Recommendations

To ensure the best results and stay safe during treatment, patients should follow these guidelines:

Pre-treatment Tests to be Performed:

• FR-alpha Testing: A biopsy of the tumor is tested to see if it has enough Folate Receptor Alpha for the drug to work.
• CA-125 Blood Test: Used to track how the cancer is responding to the medicine.
• Standard Blood Panel: Checking kidney and liver health.

Precautions During Treatment:

• Allergy Awareness: Tell your doctor immediately if you have ever had a bad reaction to a monoclonal antibody treatment.
• Stay Still: You must lie or sit comfortably during the infusion to prevent the needle from moving.

“Do’s and Don’ts” List:

• DO drink plenty of water on the day of your infusion.
• DO report any new cough or trouble breathing to your doctor right away.
• DON’T skip your pre-medication pills; they are vital for a safe infusion.
• DON’T ignore a fever that happens at home after your treatment.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Farletuzumab is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.